 Daily Mail |
Women using so much Botox it’s stopped working: Users develop antibodies …
Daily Mail A review by German researchers, published in the Journal of Neural Transmission, found that one in 200 Botox users developed antibodies, making the treatment less effective over time. Patients who needed larger doses – including those prescribed it for … |
|
Neue Therapien, Risikofaktoren und andere Neuigkeiten aus der Multiple …
DMSG Multiple Sklerose Nachrichten Eine einjährige Verlängerung einer Phase II Studie mit Daclizumab-HYP, einer veränderten Form des Daclizumab, zeigte dass monatliche Injektionen unter die Haut auch weiterhin die Schubhäufigkeit, die im MRT sichtbare Krankheitsaktivität und die … |
|
AbbVie’s Management Discusses Q1 2013 Results – Earnings Call Transcript
Seeking Alpha This includes Daclizumab, which is in Phase III development in partnership with Biogen, for relapsing remitting multiple sclerosis. Data from the first of two registrational trials, the select study, were recently published in the Lancet. And results … |
 Genetic Engineering News |
Literature Review: Which Drug Combination Will Unlock Triple-Negative Breast …
Genetic Engineering News Anti-EGFR antibodies enhance receptor ubiquitination and degradation. (A) Serum-starved HeLa cells were incubated with mAbs (10 µg/mL), a combination (each at 5 µg/mL), or with EGF (10 ng/mL), and lysates analyzed using immunoprecipitation (IP) and … |
 La Vanguardia |
Mejora la terapia de la esclerosis múltiple – La Vanguardia
La Vanguardia A medio plazo le seguirán el daclizumab, que reduce el número de brotes en un 54%, según resultados de un estudio presentado el 4 de abril en The Lancet, y el ocrelizumab, del que hay un estudio en curso en el que Montalban es el investigador principal. |
OncLiveDutch Researcher Focuses on Fc Signaling in Targeting CD20 – OncLiveOncLiveBuilding on the success achieved with rituximab (RTX), other anti-CD20 monoclonal antibodies (mAbs) are being investigated. The fully human anti-CD20 mAb ofatumumab was a…
|
New antimicrobial agents do not rely on traditional antibiotics
News-Medical.net Their inspiration was the antibodies that the immune system produces when microbes invade the body. Those antibodies patrol the body for microbes and bind to their surfaces, triggering a chain of events in which the body’s immune system attacks and … |
 Bioscience Technology |
New Antibodies Help Fight Stubborn Bacteria – Bioscience Technology
Bioscience Technology Their inspiration was the antibodies that the immune system produces when microbes invade the body. Those antibodies patrol the body for microbes and bind to their surfaces, triggering a chain of events in which the body’s immune system attacks and … |
Irish TimesBiogen Idec Management Discusses Q1 2013 Results – Earnings Call TranscriptSeeking AlphaWe expect data readouts for daclizumab in 2014, TYSABRI and SPMS in 2015 and potentially SMNrx in 2016. During that time frame, we expect to have meaning…
MedscapeChoice of First-Line Therapy in Follicular Lymphoma Debated – MedscapeMedscapeThe editorial was prompted by the publication of results from a large Italian phase 3 trial, known as FOLL05, which compared 3 chemotherapy regimens: R-CHOP (rituxima…